Table 2 Distribution of clinical factors among the various sub-groups in the gastric cancer patients’ cohort (n = 80)
Factors | H. pylori (+) cases (n = 50) | H. pylori (−) cases (n = 30) | EBV (+) cases (n = 32) | EBV (−) cases (n = 48) | MMR gene deficient (n = 32) | MMR gene proficient (n = 48) |
|---|---|---|---|---|---|---|
Anatomy | ||||||
 Proximal | 8 (16%) | 3 (10%) | 4 (12.5%) | 7 (14.58%) | 3 (9.37%) | 8 (16.66%) |
 Distal | 35 (70%) | 24 (80%) | 21 (65.62%) | 38 (79.16%) | 28 (87.5%) | 31 (64.58%) |
 Data Not available | 7 (14%) | 3 (10%) | 7 (21.87%) | 3 (6.25%) | 1 (3.12%) | 9 (18.75%) |
TNM Stage | ||||||
 I | 11 (22%) | 9 (30%) | 8 (25%) | 12(25%) | 9(28.12%) | 11(22.91%) |
 II | 9 (18%) | 5 (16.66%) | 5 (15.62%) | 9 (18.75%) | 5 (15.62%) | 9 (18.75%) |
 III | 24 (48%) | 16 (53.33%) | 17 (53.12%) | 23 (47.91%) | 17 53.12%) | 23 (47.91%) |
 IV | 2 (4%) | 0 | 1 (3.12%) | 1 (2%) | 0 | 2(4.16%) |
 Data Not available | 4 (8%) | 0 | 1 (3.12%) | 3(6.25%) | 1(3.12%) | 3(6.25%) |
Grade | ||||||
 aWD | 4 (8%) | 3 (10%) | 2 (6.25%) | 5(10.41%) | 2(6.25%) | 5(10.41%) |
 bMD | 23 (46%) | 15 (50%) | 12 (37.5%) | 26 (54.16%) | 12 (37.5%) | 26 (54.16%) |
 cPD | 20 (40%) | 11 (36.66%) | 16 (50%) | 15 (31.25%) | 17 (53.12%) | 14 (29.16%) |
 Data Not available | 3 (6%) | 1 (3.3%) | 2 (6.25%) | 2(4.16%) | 1(3.12%) | 3(6.25%) |
Family history of Cancer | ||||||
 Yes | 13 (26%) | 14 (46.66%) | 12 (37.5%) | 15 (31.25%) | 13 (40.62%) | 14 (29.16%) |
 No | 37 (74%) | 16 (53.33%) | 20 (62.5%) | 33 (68.75%) | 19 (59.37%) | 34 (70.83%) |